Contact Us

Experimental drug slows progression of Alzheimer’s: Study

An experimental Alzheimer's drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday.

  • 3
  • 8
In Phase 2 trials, lecanemab was found to slow the disease's progression by 27% over the space of 18 months, six months longer than the suggested period.